Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17641539 | 0.82 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL5946036 | 0.75 | CYP2D6 (0.32) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2237272 | 0.72 | KDM4E (0.37) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2499845 | 0.71 | MEN1 (0.37) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2347582 | 0.70 | — | — | |
| Carbamic Acid SCHEMBL30900855 | 0.70 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL968381 | 0.69 | MEN1 (0.37) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL17093961 | 0.69 | TMEM97 (0.32) | MEN1KMT2A | |
| SCHEMBL246225 | 0.68 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL6228764 | 0.68 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12286411-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-04-29 | — | — | US | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-3601224-B1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2023-07-05 | — | — | EP | disclosed |
| EP-4125883-A1 | COMBINATION THERAPY | Antabio SAS (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-20210347748-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2021-11-11 | — | — | US | disclosed |
| WO-2021191240-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2021-09-30 | — | — | WO | disclosed |
| EP-3856729-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2021-08-04 | — | — | EP | disclosed |
| EP-3027615-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2021-07-21 | — | — | EP | disclosed |
| US-11000511-B2 | Chemical compounds as antibiotics | ANTABIO SAS (FR) | 2021-05-11 | — | — | US | disclosed |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2020-05-21 | — | — | US | disclosed |
| WO-2020064173-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2020-04-02 | — | — | WO | disclosed |
| EP-3628666-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Antabio SAS (FR) | 2020-04-01 | — | — | EP | disclosed |
| EP-3601224-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | Antabio SAS (FR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172423-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2018-09-27 | — | — | WO | disclosed |
| US-20160185774-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2016-06-30 | — | — | US | disclosed |
| EP-3027615-A2 | ANTI-INFECTIVE COMPOUNDS | Institut Pasteur Korea (KR) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015014993-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2015-02-05 | — | — | WO | disclosed |
| WO-2010001220-A1 | NEW 1,2,4-TRIAZINE DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS SA (FR) | 2010-01-07 | — | — | WO | disclosed |
| EP-2141164-A1 | New 1,2,4-triazine derivatives and biological applications thereof | Mutabilis (FR) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12286411-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | MEN1 1135/4885KMT2A 3671/4885HTT 4559/4885 |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | MRPL21, CFTR, H1-0 | MEN1 569/4885KMT2A 825/4885HTT 4197/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | MEN1 2052/4885KMT2A 2615/4885HTT 3701/4885 |
| US-20160185774-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | MEN1 3685/4885KMT2A 4781/4885HTT 3860/4885 |
| US-11000511-B2 | Chemical compounds as antibiotics | MRPL21, CFTR, H1-0 | MEN1 569/4885KMT2A 825/4885HTT 4197/4885 |
| US-20210347748-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | INSR, INSRR, ARG1 | MEN1 1447/4885KMT2A 3696/4885HTT 4599/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | MEN1 4188/4885KMT2A 1791/4885HTT 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.